Genmab — Februar 2019

[E_L]

Pollux completion date extended by half a year https://clinicaltrials.gov/ct2/history/NCT02076009?A=39&B=40&C=merged

[E_L]

I think they are giving MAIA participants on (Rd) arm who have sponsor-confirmed disease progression , the option to receive daratumumab https://clinicaltrials.gov/ct2/history/NCT02252172?A=47&B=48&C=merged

[E_L]

ethical decision?

[E_L]

ALL hospitals now recruiting in the HuMax-AXL-ADC trial (1 hospital removed) https://clinicaltrials.gov/ct2/history/NCT02988817?A=11&B=12&C=merged

[Solsen]

Full speed

[Bulder]

E L 17:41: That is the cross over problem we have discussed earlier. When they do that they

[Bulder]

will never get a reliable OS, as there is no control group to compare with.

[Bulder]

But maybe they have realized that Rd-pts would do it any way (cross over).

[E_L]

maybe. i guess you can not stop them from taking Dara if they want to.

[E_L]

...just for the purpose of a 'clean' trial

[Bulder]

xactly, they can leave the study any time and pay for dara themselves. But now Janssen will pay for them. Nice move.

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[peter12]

Interessant artikel om atezo + dara https://www.medpagetoday.com/reading-room/asco/immunotherapy/78028

[peter12]

Og det må være dette forsøg der er udvidet ? https://clinicaltrials.gov/ct2/show/NCT02431208?cond=NCT02431208&rank=1

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen. :-). Skyfri himmel over Sæby.

[Helge_LarsenPI-redaktør]

Ditto her i Regstrup.

[Darvin]

Kan ikke huske om denne blev del den anden dag https://www.targetedonc.com/videos/key-takeaway-points-in-phase-iii-alcyone-trial-for-multiple-myeloma

[Hamming]

Fedt svar fra Lassen https://twitter.com/Genmab/status/1093814035416522752

[henrik48]

Når Lassen siger ok så er der bestemt noget at komme efter !!!